Skip to main content

Biotage Q4 Sales Increase 30 Percent; CEO Bork to Step Down

NEW YORK, Feb. 9 (GenomeWeb News) - Biotage today reported a 30-percent increase in net sales as part of its fiscal fourth-quarter earnings for 2005, and the company separately said in a statement that CEO Jeff Bork will be replaced by Torben Jörgensen, the former CEO of Affibody, effective April 27.

 

Net sales for the three months ended Oct. 1 increased 30 percent to SEK 138 million ($17.8 million) from SEK 106 million year over year.

 

R&D spending for the quarter slid to SEK 17.5 million from SEK 19.4 million in the year-ago period.

 

Fourth-quarter profit rose to SEK 2.3 million from a loss of SEK 10.6 million year over year.

 

The company had about SEK 52.8 million in cash and cash equivalents as of Dec. 31.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.